Skip to main content

Advertisement

SpringerLink
Log in

Characteristics and uses of IL-2 in immunotherapy

  • Published:
Biotherapy

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ehrlich P. In: Himmelweit F, ed. The collected papers of Paul Ehrlich, Vol. 2. Oxford: Pergamon, 1957: 550–62.

    Google Scholar 

  2. Bolhuis RLH, Gravekamp C, van de Griend gnRJ. Cell-cell interactions. In: Clinics in immunology and allergy. 1986: 29–90.

  3. Takasugi M, Mickey MR, Terasaki PI. Studies on specificity of cell-mediated immunity to human tumors. J Nat Cancer Inst 1974; 53: 1527–38.

    Google Scholar 

  4. Ortaldo JR, Longo DL. Human natural lymphocyte effector cells: definition, analysis of activity and clinical effectiveness. J Natl Cancer Inst 1988; 80: 999–1010.

    Google Scholar 

  5. Herberman RB. Natural cell mediated immunity against tumors. New York: Academic Press, 1980.

    Google Scholar 

  6. Herberman RB, Ortaldo JR. Natural killer cells: their role in defenses against disease. Science 1981; 214: 24–30.

    Google Scholar 

  7. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495.

    Google Scholar 

  8. van de Griend RJ, Bolhuis RLH. Rapid expansion of allospecific cytotoxic t cell clones using nonspecific feeder cell lines without further addition of exogeneous IL-2. Transplantation 1984; 38: 401–6.

    Google Scholar 

  9. van de Griend RJ, van Krimpen BA, Bol SJL, Thompson A, Bolhuis RLH. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat labile serum component and by various types of feeder cells. J of Immunol Methods 1984; 66: 285–98.

    Google Scholar 

  10. Bolhuis RLH, Braakman E, van de Griend RJ. Are cognitive receptors involved in “non specific” MHC-unrestricted lytic activity? In: Annales Institut Pasteur/Immunologie 1988; 139: 460–65.

    Google Scholar 

  11. Hersey P, Bolhuis RLH. “Non specific” MHC-unrestricted killer cells and their receptors. Immunology Today 1987; 8: 233–39.

    Google Scholar 

  12. Bolhuis RLH, Braakman E. Lymphocyte mediated responses: activation of and lysis by, cytotoxic lymphocytes. Ed. Current Science Ltd. ISSN 0952-7915, Current Opinion in Immunology 1988; 1: 236–40.

    Google Scholar 

  13. Lanier LL, Le AN, Civin CIet al. The relationship of CD16 (Leu11) and Leu19 (NKH1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480–86.

    Google Scholar 

  14. Hercend T, Griffin JD, Benussan Aet al. Generation of monoclonal antibodies to a human natural killer clone. J Clin Invest 1985; 75: 932–43.

    Google Scholar 

  15. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD 16/Leu1 l antigen). J Exp Med 1985; 162: 2089–106.

    Google Scholar 

  16. Allavena P, Ortaldo JR. Characteristics of human NK clones: target specificity and phenotype. J Immunol 1984; 132: 2363.

    Google Scholar 

  17. Bolhuis RLH, van de Griend RJ, Ronteltap CPM. Clonal expansion of human B73.1 positive natural killer cells or large cytotoxicity and occasionally lectin dependent cytotoxicity. Natl Immun Cell Growth Regul 1983/1984; 3: 61–72.

    Google Scholar 

  18. Bolhuis RLH, van de Griend RJ, Phytohemagglutinin induced proliferation and cytolytic activity in T3+ but not in T3− cloned T3 lymphocytes requires the involvement of the T3 antigen for signal transmission. Cell Immunol 1985; 93: 46–57.

    Google Scholar 

  19. Welsh RM. Natural killer cells and interferon. CRC Crit Rev Immunol 1984; 5: 55–93.

    Google Scholar 

  20. Borst J, van de Griend RJ, van Oostveen H, Ang S, Melief CJM, Seidman JG, Bolhuis RLH. A T cell receptorγ/CD3 complex found on cloned functional lymphocytes. Nature 1987, 325; 683–8.

    Google Scholar 

  21. van de Griend RJ, Borst J, Tax WJM, Bolhuis RLH. Functional reactivity of WT31 monoclonal antibody with TCRγ expression CD3+4−8−T cells. J Immunol 1988; 140:4, 1107–10.

    Google Scholar 

  22. van de Griend RJ, Tax WJM, van Krimpen BA, Vreugdenhil RJ, Bolhuis RLH. Lysis of tumor cells by CD3+4−8−16+T cell receptorαβ- clones regulated via CD3 and CD16 activation sites, recombinant Interleukin-2 and Interferonβ. J Immunol 1987; 138: 1627–33.

    Google Scholar 

  23. van de Griend RJ, van Dijk J, Fleuren GJ, Goedegebuure SP, Bolhuis RLH. Induction of lysis by crosslinked antibodies. In: Human Tumor Antigens and Specific Tumor Therapy, Ed. AR Liss Inc. 1989; pp 221–30.

  24. Ortaldo JR, Sharrow SO, Timonen Tet al. Determination of surface antigens on highly purified human Nk cells by flow cytometry with monoclonal antibodies. J Immunol 1978; 121: 304–11.

    Google Scholar 

  25. 25.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 1985; 313: 1485–92.

    Google Scholar 

  26. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 1987; 316: 889–97.

    Google Scholar 

  27. West WH, Tauer KW, Yanelli JR, Marshall GD, Off DW, Thuraman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 1987; 316: 898–905.

    Google Scholar 

  28. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988; 208: 121–35.

    Google Scholar 

  29. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Wash, DC) 1986; 233: 1318–21.

    Google Scholar 

  30. Spiess P, Yang JC, Rosenberg SA. In vivo activity of murine tumor-infiltrating lymphocytes. J Natl Cancer Inst 1987; 79: 1067–75.

    Google Scholar 

  31. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immuneresponses against autologous tumor. J Immunol 1987; 138: 989–95.

    Google Scholar 

  32. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res 1988; 48: 206–14.

    Google Scholar 

  33. Heo DS, Whiteside TL, Johnson JT, Ghen K, Barners EL, Herberman RB. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 1987; 47: 6353–62.

    Google Scholar 

  34. Topalian SL, Solomon Davis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6: 839–53.

    Google Scholar 

  35. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Eng J Med 1988; 319: 1676–80.

    Google Scholar 

  36. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA. Tumor localization of adoptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250–61.

    Google Scholar 

  37. Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokinesin vivo andin vitro. Cancer Res 1988; 48: 5818–24.

    Google Scholar 

  38. Cameron R, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine metastases. Cancer Res 1988; 48: 5810–17.

    Google Scholar 

  39. Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 1988; 80: 1393–97.

    Google Scholar 

  40. Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 1988; 41: 609–15.

    Google Scholar 

  41. Lanzavecchia A, Staerz UD. Lysis of nonnucleated red blood cells by cytotoxic T lymphocytes. Eur J Immunol 1987: 1073–74.

  42. van Dijk J, Warnaar SO, van Eendenburg JDH, Thienpont M, Braakman E, Boot JHA, Fleuren GJ, Bolhuis RLH. Induction of tumor cell lysis by bispecific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int J Cancer 1989; 43: 344–49.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Immunology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    R. L. H. Bolhuis

  2. Dept. of Internal Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    G. Stoter

  3. Dept. of Surgical Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    A. M. M. Eggermont

Authors
  1. R. L. H. Bolhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Stoter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolhuis, R.L.H., Stoter, G. & Eggermont, A.M.M. Characteristics and uses of IL-2 in immunotherapy. Biotherapy 1, 153–159 (1989). https://doi.org/10.1007/BF02170884

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02170884

Keywords

Search

Navigation